Chapel Hill-based pharmaceutical company raises $200,000
Chapel Hill, N.C. — A Chapel Hill-based pharmaceuticals company raised $200,000 from one investor, according to a filing with the Securities and Exchange Commission.
AimMax Therapeutics Inc. filed the Form D on April 17. The first sale occurred on April 14. According to the filing, the company does not intend the offering to last more than one year, and it is not being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer.
Founded in 2016, the company aims to research and develop pharmaceuticals and therapeutics for the treatment and prevention of diseases.
The company claimed a Rule 506 (b) exemption for the filing. Companies relying on the Rule 506 exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically with the SEC after they first sell their securities.
Laurene Wang, president and CEO of AimMax Therapeutics, signed the Form D on April 17. She is founder and scientific director of INDAPharma LLC, a pharmaceutical consulting company. The Form D can be found here.
Note: This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism
Please Log In to add a comment.
Latest for Insiders
- Dr. James Goodnight: From moment of inspiration to building SAS, a global software powerhouse
- With all tickets gone, TechWire Awards to be streamed live at WRAL.com
- As Scot Wingo's new gig Spiffy lands extra $2.5M, he 'loves' being back with a startup
- Dr. Charles Hamner: A creator of NC's life science industry
- First WRAL TechWire Hall of Famers: Five pillars of NC's tech success
- Why Red Hat's new CFO left IBM - and what he likes better
- Eric Shander's journey: From IBM to Red Hat, chief accounting officer to CFO
- Datathon at Duke offers big talent recruiting opportunity, says former Red Hat exec
- 'Life is more than self'- The driver for 2017 WRAL TechWire awards
- SEC's big 'fake news' crackdown shows a major threat to readers, investors